YOUR SEARCH :
Industry: Pharmaceutical
YOUR SEARCH PRODUCED 86 MATCHES. PAGE 7 of 9 Items 61-70 of 86
Law, Ethics and Technology (LHC503)
Author: Bishara, Norman
Product Type: Syllabi
Source: University of Michigan Ross School of Business
Publication Year: 2005
Ultimately, the course aims to assist you in a business career by equipping you with an understanding of the constraints the legal system and ethics put on the use and commercialization of advances in scientific knowledge...
Responsible Lobbying?
Author: Baron, David P.
Product Type: Cases
Source: Harvard Business School
Publication Year: 2008
In 2006 Merck received FDA approval for Gardasil, the first vaccine for human papilloma virus (HPV) which had been identified as the cause of cervical cancer. Prior to FDA approval, Merck began to develop a market for Gardasil and launched an intensive campaign to get states to make HPV vaccination of girls entering middle school mandatory.
Chonqing Peace Medical Corporation Ltd (A, B)
Authors: Fratantuono, Michael J.; Li, Zhuoran
Product Type: Cases
Source: University of Hong Kong
Publication Year: 2009
The case describes the evolution of Peace Medical over its first seven years of operations, and culminates by asking students to assess the company's strengths and possible weaknesses.
Genentech's Dilemma: Avastin vs Lucentis
Author: Boscheck, R.
Product Type: Cases
Source: IMD - International Institute for Management Development
Publication Year: 2008
On 19 October, 2007, Herb Kohl, the Chairman of the US Senate's Special Committee on Aging, asked Genentech to clarify its decision to limit the availability of its product Avastin in favour of its more expensive drug Lucentis, both applied in the treatment of wet age-related macular degeneration.
Consumer Awareness or Disease Mongering? GlaxoSmithKline and the Restless Legs Syndrome
Author: Baron, David P.
Product Type: Cases
Source: Harvard Business School
Publication Year: 2008
In 2005, GlaxoSmithKline (GSK) received approval from the Food and Drug Administration (FDA) to market Requip (Ropinirole) for Restless Leg Syndrome. This case explores GSK's tactics and the distinction between raising awareness and inappropriately promoting a drug.
SMA
Authors: Beer, Michael; Tushman, Michael L.
Product Type: Cases
Source: Harvard Business Publishing
Publication Year: 2005
The Micro-Electronic Products Division of SMA has financial and organizational problems. Conflict and lack of coordination exist between functional groups. Employees do not have a sense of direction and morale is low. The cause of these problems is found in a change in business environment followed by change in organization and management. A rewritten version of an earlier case.
Merck Latin America (A, B, C, D)
Authors: Beer, Michael; Weber, James
Product Type: Cases
Source: Harvard Business Publishing
Publication Year: 2002
Introduces Grey Warner, the vice president of Merck's Latin America region, and his efforts to improve the organizational effectiveness of the region and to introduce a more global business culture and values. Discusses Merck's ethics and values, its Latin American organization, the change methodologies used, and the political and economic conditions in the region.
GSK's Andrew Witty: Addressing Neglected Tropical Diseases and Global Health Issues (A, B)
Authors: Rouse, Michael J.; Sehgal, Chander
Product Type: Cases
Source: Richard Ivey School of Business
Publication Year: 2011
Andrew Witty reflected on his vision for big pharma as a catalyst for change which focussed on two key issues: 1) promoting innovation for the products that treat or prevent neglected tropical diseases and 2) improving access to medicines in the world's poorest countries.
Cipla 2011
Authors: Deshpande, Rohit; Sucher, Sandra J.; Winig, Laura
Product Type: Cases
Source: Harvard Business School
Publication Year: 2011
The head of Cipla is weighing options for how to continue to support the global fight against HIV/AIDS while positioning his company for growth in a changing regulatory landscape.
The Business of Birth Control
Authors: Spar, Debora L.; Huntsberger, Briana
Product Type: Journal Articles
Source: Harvard Health Policy Review, Vol. 6, No. 1, Spring 2005
Publication Year: 2005
More so than most, the business of birth control is driven, not by technological breakthrough or commercial innovation, but by the politics that allow innovation to reach the market.
YOUR SEARCH PRODUCED 86 MATCHES. PAGE 7 of 9 Items 61-70 of 86